Finding the "killer app" for treating obese individuals has seen no shortage of efforts result in failure over the years. The slow start of VIVUS' (VVUS) Qsymia has investors doubting the market potential of both it and Arena Pharmaceuticals' (ARNA) new drugs targeting the problem. In the following video, health care bureau chief Brenton Flynn runs through yet another example of a novel obesity treatment approach that seems destined for failure from EnteroMedics (NASDAQ: ETRM).
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.